Compare HPI & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HPI | BIOA |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.6M | 481.0M |
| IPO Year | 2002 | 2024 |
| Metric | HPI | BIOA |
|---|---|---|
| Price | $16.12 | $10.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 39.7K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 66.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,995,000.00 |
| Revenue This Year | N/A | $720.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.26 | $4.38 |
| 52 Week High | $17.61 | $25.96 |
| Indicator | HPI | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 46.48 | 31.45 |
| Support Level | $16.07 | $7.95 |
| Resistance Level | $16.38 | $13.17 |
| Average True Range (ATR) | 0.12 | 1.22 |
| MACD | 0.01 | -0.51 |
| Stochastic Oscillator | 50.00 | 11.78 |
John Hancock Preferred Income Fund is a closed-end, diversified management investment company. Its primary investment objective is to provide a high-level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve its investment objectives by investing in securities that may be undervalued relative to similar securities in the marketplace. The fund's principal investment strategies include investing a majority of its assets in preferred stocks and other preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, and short-term investments.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.